The major determinants of resistance to venetoclax in MCL and CLL patients have been identified as the overexpression and de novo synthesis of BCL-XL and MCL-1, antiapoptotic proteins belonging to the BCL2 family (20). The gene discussed is BCL2; the disease is mantle cell lymphoma.